Thyrotropin Receptor Antibody, Serum

Test Code

TRAB

Alias/See Also

Epic: LAB574
Mayo: THYRO

Antibodies to TSH receptor
Inhibitory Immunoglobulin
Long-Acting Thyroid Stimulator (LATS)
TBII (TSH-Binding Inhibiting Immunoglobulin)
Thyroid-Stimulating Hormone Receptor (TSH Receptor) Antibody
TRAb (Thyrotropin Receptor Antibody)
TSH (Thyroid-Stimulating Hormone) Receptor Binding
TSH Binding Inhibition Index
TSH Receptor (Thyroid-Stimulating Hormone Receptor) Antibody
TSH-Binding Inhibiting Immunoglobulin (TBII)
Graves Disease
Graves' Disease

CPT Codes
83520

Preferred Specimen

Specimen Type: Serum
Collection Container: Serum gel
Specimen Volume: 1 mL

Patient Preparation

For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Patient should not be receiving heparin treatment.

Minimum Volume

0.75 mL

Other Acceptable Specimens

Collection Container: Red top

Instructions

Centrifuge and aliquot serum into a plastic vial.

Transport Container

Plastic vial

Specimen Stability

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	7 days
	Frozen	90 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Gross hemolysis	Reject
Gross lipemia	OK
Gross icterus	Reject

Methodology
Electrochemiluminescence Immunoassay

Setup Schedule

Monday through Saturday

Report Available

1 to 3 days

Limitations

CAUTIONS
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. The presence of antibodies to streptavidin or ruthenium can also rarely occur and may also interfere in this assay. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.

SUPPORTIVE DATA
A Mayo method comparison study between this assay and the Kronus TSH Receptor Antibody binding inhibition assay showed an overall agreement between the assays of 96.5% and a calculated Kappa statistic of 0.93.

Reference Range

REFERENCE VALUES
< or =1.75 IU/L

INTERPRETATION
The sensitivity and specificity of an elevated thyrotropin receptor antibody (TRAb) test for Graves disease (GD) diagnosis depends on whether patients have disease treated with antithyroid drugs or clinically active, untreated disease. Based on a study that included specimens from 436 apparently healthy individuals, 210 patients with thyroid diseases without diagnosis of GD, and 102 patients with untreated GD, a decision limit of 1.75 IU/L showed a sensitivity of 97% and a specificity of 99% for detection of GD.(1) In healthy individuals and in patients with thyroid disease without diagnosis of GD, the upper limit of antithyrotropin receptor values are 1.22 IU/L and 1.58 IU/L, respectively (97.5th percentiles). A Mayo study of 115 patients, including 42 patients with GD, showed a sensitivity of 95% and a specificity of 97% for detection of GD at a decision limit of 1.75 IU/L.

Assessment of TRAb status is particularly relevant in women who have undergone thyroid ablative therapy or are on active antithyroid treatment and, therefore, no longer display biochemical or clinical evidence of thyrotoxicosis. Significant neonatal thyrotoxicosis is likely if a pregnant woman with a history of GD has TRAb concentrations of more than 3.25 IU/L during the last trimester, regardless of her clinical remission status. Lesser elevations are only occasionally associated with neonatal thyrotoxicosis.

Gestational thyrotoxicosis, which is believed to be due to a combination of human chorionic gonadotropin cross-reactivity on the thyrotropin receptor and transient changes in thyroid hormone protein binding, is only very rarely associated with an elevated TRAb test. Finding an elevated test result in this setting usually suggests underlying GD.

An elevated TRAb test at the conclusion of a course of antithyroid drug treatment is highly predictive of relapse of GD. However, the converse, a normal TRAb test, is not predictive of prolonged remission.

Clinical Significance

USEFUL FOR
Recommended first-line test for detection of thyrotropin receptor antibodies

The following situations:

Differential diagnosis of etiology of thyrotoxicosis in patients with ambiguous clinical findings and/or contraindicated (eg, pregnant or breast-feeding) or nondiagnostic thyroid radioisotope scans
Diagnosing clinically suspected Graves disease (GD) (eg, extrathyroidal manifestation of GD include endocrine exophthalmos, pretibial myxedema, thyroid acropachy) in patients with normal thyroid function tests
Determining the risk of neonatal thyrotoxicosis in a fetus of a pregnant female with active or past active GD
Differential diagnosis of gestational thyrotoxicosis versus first trimester manifestation or recurrence of GD
Assessing the risk of GD relapse after antithyroid drug treatment

CLINICAL INFORMATION
Autoimmune thyroid disease is characterized by the presence of autoantibodies against various thyroid components, namely the thyrotropin receptor, thyroid peroxidase, and thyroglobulin, as well as by an inflammatory cellular infiltrate of variable severity within the gland.

Among the autoantibodies found in autoimmune thyroid disease, thyrotropin receptor autoantibodies (TRAb) are most closely associated with disease pathogenesis. All forms of autoimmune thyrotoxicosis (Graves disease [GD], Hashitoxicosis, neonatal thyrotoxicosis) are caused by the production of stimulating TRAb-. These autoantibodies, also known as long-acting-thyroid-stimulators or thyroid-stimulating immunoglobulins (TSI), bind to the receptor and transactivate it, leading to stimulation of the thyroid gland independent of the normal feedback-regulated thyrotropin stimulation.

Some patients with GD also have TRAb that do not transactivate the thyrotropin receptor. The balance between stimulating and blocking antibodies, as well as their individual titers, is felt to be a determinant of GD severity. Some patients with autoimmune hypothyroidism also have evidence of either blocking TRAb or, rarely, TSI.

TRAb may be detected before autoimmune thyrotoxicosis becomes biochemically or clinically manifest. Since none of the treatments for GD are aimed at the underlying disease process but rather ablate thyroid tissue or block thyroid hormone synthesis, TSI may persist after apparent clinical cure. This is of particular relevance for pregnant women with a history of GD that was treated with thyroid-ablative therapy. Some of these women may continue to produce TSI. Since TSI are IgG antibodies, they can cross the placental barrier causing neonatal thyrotoxicosis.

While the gold standard for thyroid-stimulating immunoglobulins is the bioassay (see TSI / Thyroid-Stimulating Immunoglobulin, Serum), the TRAb test has a shorter turnaround time, less analytical variability, and is less expensive.

Performing Laboratory
Mayo Clinic Laboratories - Rochester
3050 Superior Drive NW
Rochester, MN 55901

Additional Information
Thyrotropin Receptor Antibody, Serum

Last Updated: December 18, 2023
Last Review: N. Wolford, December 18, 2023

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.